Erythropoietin (EPO) requirements remain high in EPO resistant patients after iron repletion

ASAIO Journal

Volumn 44, Issue 5, 1998, Pages

  Cohen, Debbie ^a   Raja, Rasib M ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DOSAGE; HORMONES; IRON; PATIENT MONITORING;

HEMODIALYSIS;

DIALYSIS;

ALUMINUM; IRON; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; UREA;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL;

EID: 0032170497     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-199809000-00058     Document Type: Article

References (12)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73-78, 1987.
2. Van Wyck DB: Iron deficiency in patients with dialysis associated anemia during erythropoietin replacement therapy: strategies for assessment and management. Semin Nephrol 9(Suppl 2): 21-24, 1989.
3. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden D: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35: 712-716, 1989.
4. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28: 529-534, 1996.
5. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic iron supplementation. Am J Kidney Dis 26: 41-46, 1995.
6. Fishbane S, Lynn RI: The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 44: 238-240, 1995.
7. Danielson B: R-HuEPO hyporesponsiveness: who and why? Nephrol Dial Transplant 10(Suppl 6): 69-73, 1995.
8. Cannata JB, Gomez AC, Fernandez SI, MacGregor S, Menedez-Fraga P, Brock JH: Iron uptake in aluminum overload: in vivo and vitro. Nephrol Dial Transplant 6: 637-642, 1991.
9. Valderrebano F: Erythropoietin in chronic renal failure. Kidney Int 50: 1373-1391, 1996.
10. Kalentar-Zadeh K, Kleiner M, Dunne E, Ahem K, Nelson M, et al: Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 31: 263-272, 1998.
11. Cohen D, Bloom R: Erythropoietin (rHuEPO) requirements are inversely related to iron saturation levels (FeSats) in chronic stable hemodialysis patients (Abstract). J Am Soc Nephrol 7: 1442, 1996.
12. Barany P, Divino-Filho JC, Bergsham J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29: 565-568, 1997.